Association of β-Blocker Use With Heart Failure Hospitalizations and Cardiovascular Disease Mortality Among Patients With Heart Failure With a Preserved Ejection Fraction A Secondary Analysis of the TOPCAT Trial

被引:118
|
作者
Silverman, Daniel N. [1 ]
Plante, Timothy B. [1 ]
Infeld, Margaret [1 ]
Callas, Peter W. [1 ]
Juraschek, Stephen P. [2 ]
Dougherty, Geoff B. [3 ]
Meyer, Markus [1 ]
机构
[1] Univ Vermont, Larner Coll Med, Dept Med & Biostat Unit, Burlington, VT 05401 USA
[2] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Med, Boston, MA 02115 USA
[3] Johns Hopkins Univ, Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA
基金
美国国家卫生研究院;
关键词
MYOCARDIAL-INFARCTION; CLINICAL-OUTCOMES; EXERCISE CAPACITY; NATRIURETIC PEPTIDES; RANDOMIZED-TRIAL; ELDERLY-PATIENTS; CIBIS-II; CARVEDILOL; SPIRONOLACTONE; INTERVENTION;
D O I
10.1001/jamanetworkopen.2019.16598
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
IMPORTANCE beta-Blockers are prescribed to most patients with heart failure (HF) with a preserved ejection fraction (HFpEF), but their effect on HFpEF remains unclear. OBJECTIVE To determine the association of beta-blocker use with HF hospitalizations and cardiovascular disease (CVD) mortality, overall and in strata of patients with an ejection fraction (EF) of 50% or greater or less than 50%. DESIGN, SETTING, AND PARTICIPANTS For 1761 participants from North and South America enrolled in the multicenter, double-blinded Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist randomized clinical trial of spironolactone for patients with HFpEF between August 10, 2006, and January 31, 2012, the association of baseline beta-blocker use with HF hospitalization and CVD mortality was analyzed using unadjusted and adjusted Cox proportional hazards regression models, overall and in strata of patients with an EF of 50% or greater or less than 50%. Participants had symptomatic HF with a left ventricular EF of 45% or greater, with enrollment based on either hospitalization attributed to decompensated HF in the prior year or elevated natriuretic peptide levels. Statistical analysis was performed from January 31 to May 2, 2019. EXPOSURE Use of beta-blockers. MAIN OUTCOMES AND MEASURES Incident HF hospitalization and CVD mortality. RESULTS Among 1761 participants included in the analysis (879 women and 882 men; mean [SD] age, 71.5 [9.6] years), 1394 (79.2%) reported beta-blocker use and 1567 (89.0%) had an EF of 50% or greater. Hospitalizations for HF occurred for 399 participants (22.7%), and CVD mortality occurred for 229 participants (13.0%). Use of beta-blockers was associated with a higher risk of HF hospitalization among patients with HFpEF with an EF of 50% or greater (hazard ratio, 1.74 [95% CI, 1.28-2.37]; P < .001) but not among patients with an EF between 45% and 49%(hazard ratio, 0.68 [95% CI, 0.28-1.63]; P = .39). There was a significant interaction between beta-blocker use and EF threshold for incident HF hospitalizations (P = .03). Use of beta-blockers was not associated with a change in CVD mortality. CONCLUSIONS AND RELEVANCE For patients with an EF of 50% or greater, beta-blocker use was associated with an increased risk of HF hospitalizations but not CVD mortality. For patients with an EF between 45% and 49%, there was no such association.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] Recurrent heart failure hospitalizations in heart failure with preserved ejection fraction: an analysis of TOPCAT trial
    Wang, Qi
    Yu, Fei
    Su, Hao
    Liu, Zhiquan
    Hu, Kai
    Wu, Guohong
    Yan, Ji
    Chen, Kangyu
    Yang, Dongmei
    ESC HEART FAILURE, 2024, 11 (01): : 475 - 482
  • [2] Anemia, Mortality, and Hospitalizations in Heart Failure With a Preserved Ejection Fraction (from the TOPCAT Trial)
    Gupta, Kartik
    Kalra, Rajat
    Rajapreyar, Indranee
    Joly, Joanna M.
    Pate, Mike
    Cribbs, Marc G.
    Ather, Sameer
    Prabhu, Sumanth D.
    Bajaj, Navkaranbir S.
    AMERICAN JOURNAL OF CARDIOLOGY, 2020, 125 (09): : 1347 - 1354
  • [3] Association of Baseline Diuretic Use With Cardiovascular Outcomes in Patients With Heart Failure With Preserved Ejection Fraction: A Secondary Analysis From TOPCAT
    Khan, Sadiya S.
    Huffman, Mark D.
    Harrington, Katherine
    Baldridge, Abigail S.
    Yu, Jie
    Neal, Bruce
    Arnott, Clare
    Shah, Sanjiv J.
    JOURNAL OF CARDIAC FAILURE, 2021, 27 (07) : 816 - 818
  • [4] Association of Natriuretic Peptides With Cardiovascular Prognosis in Heart Failure With Preserved Ejection Fraction Secondary Analysis of the TOPCAT Randomized Clinical Trial
    Myhre, Peder Langeland
    Vaduganathan, Mutheah
    Claggett, Brian L.
    Anand, Inder S.
    Sweitzer, Nancy K.
    Fang, James C.
    O'Meara, Eileen
    Shah, Sanjiv J.
    Desai, Akshay S.
    Lewis, Ekirin F.
    Rouleau, Jean
    Pitt, Bertram
    Pfeffer, Marc A.
    Solomon, Scott D.
    JAMA CARDIOLOGY, 2018, 3 (10) : 1000 - 1005
  • [5] Do beta-blockers increase the risk for hospitalizations in heart failure with preserved ejection fraction? A secondary analysis of beta-blocker use in the TOPCAT trial
    Silverman, D. N.
    Plante, T. B.
    Infeld, M. I.
    Juraschek, S. P.
    Dougherty, G.
    Meyer, M. F.
    EUROPEAN HEART JOURNAL, 2019, 40 : 967 - 967
  • [6] Previous heart failure hospitalization, spironolactone, and outcomes in heart failure with preserved ejection fraction - a secondary analysis of TOPCAT
    Szabo, Barna
    Benson, Lina
    Savarese, Gianluigi
    Hage, Camilla
    Fudim, Marat
    Devore, Adam
    Pitt, Bertram
    Lund, Lars H.
    AMERICAN HEART JOURNAL, 2024, 271 : 136 - 147
  • [7] Atrial Fibrillation in Heart Failure With Preserved Ejection Fraction The TOPCAT Trial
    Cikes, Maja
    Claggett, Brian
    Shah, Amil M.
    Desai, Akshay S.
    Lewis, Eldrin F.
    Shah, Sanjiv J.
    Anand, Inder S.
    O'Meara, Eileen
    Rouleau, Jean L.
    Sweitzer, Nancy K.
    Fang, James C.
    Saksena, Sanjeev
    Pitt, Bertram
    Pfeffer, Marc A.
    Solomon, Scott D.
    JACC-HEART FAILURE, 2018, 6 (08) : 689 - 697
  • [8] Systolic blood pressure and cardiovascular outcomes in heart failure with preserved ejection fraction: an analysis of the TOPCAT trial
    Selvaraj, Senthil
    Claggett, Brian
    Shah, Sanjiv J.
    Anand, Inder
    Rouleau, Jean L.
    Desai, Akshay S.
    Lewis, Eldrin F.
    Pitt, Bertram
    Sweitzer, Nancy K.
    Pfeffer, Marc A.
    Solomon, Scott D.
    EUROPEAN JOURNAL OF HEART FAILURE, 2018, 20 (03) : 483 - 490
  • [9] Impact of pulmonary disease on the prognosis in heart failure with preserved ejection fraction: the TOPCAT trial
    Ramalho, Sergio H. R.
    Claggett, Brian L.
    Sweitzer, Nancy K.
    Fang, James C.
    Shah, Sanjiv J.
    Anand, Inder S.
    Pitt, Bertram
    Lewis, Eldrin F.
    Pfeffer, Marc A.
    Solomon, Scott D.
    Shah, Amil M.
    EUROPEAN JOURNAL OF HEART FAILURE, 2020, 22 (03) : 557 - 559
  • [10] Prognostic Impact of Cardiovascular Versus Noncardiovascular Hospitalizations in Heart Failure With Preserved Ejection Fraction: Insights From TOPCAT
    Barkoudah, Ebrahim
    Claggett, Brian L.
    Lewis, Eldrin f.
    O'meara, Eileen
    Clausell, Nadine
    Diaz, Rafael
    Fleg, Jerome l.
    Pitt, Bertram
    Rouleau, Jean L.
    Solomon, Scott D.
    Pfeffer, Marc A.
    Desai, Akshay S.
    JOURNAL OF CARDIAC FAILURE, 2022, 28 (09) : 1390 - 1397